



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017

Tel. : 0731-2723016, 4066516 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-2426700, 2420926, 2524003, Fax : 0731-2420926 • CIN : L24233MP1985PLC002709

To,
The Company Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001(M.H.)

Date: 30/05/2015

To,
The Company Secretary
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Sub. : Audited Financial results for the Quarter as well as year ended 31st March, 2015.

Dear Sirs,

In compliance with Clause 41 of the Listing Agreement, we are submitting herewith the Audited Financial results for the quarter as well as year ended on 31st March, 2015 duly approved by the board of the Directors of the Company in their meeting held on 30/05/2015.

This is for your information and record.


Thanking you,
Yours Faithfully
For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
(DIN No: 00028819)



AUDITED FINANCIAL RESULTS FOR THE QUARTER AS WELL AS YEAR ENDED March 31, 2015

PART I		(Rs in Lakhs) (Except EPS & Number of Share)				
	Particulars	For the Quarter ended March 31, 2015	For the Quarter ended December 31, 2014	For the Quarter ended March 31, 2014	Audited For The Year Ended March 31, 2015	Audited For The Year Ended March 31, 2014
	(Refer Notes Below)	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1	Income from operations					
	(a) Net sales/ income from operations (Net of Excise duty)	263.42	71.26	113.24	456.45	488.88
	(b) Other operating income	114.09	15.62	112.72	129.71	228.28
	Total income from operations (net)	377.51	86.88	225.97	586.15	717.17
2	Expenses					
	(a) Cost of materials consumed	52.78	22.93	13.88	109.86	153.78
	(b) Purchases of stock-in-trade	198.13	41.42	106.21	276.27	308.10
	(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	11.21	(8.15)	(9.55)	1.95	18.17
	(d) Employee benefits expense	27.70	8.62	24.62	49.71	41.30
	(e) Depreciation and amortisation expense	5.04	8.90	6.46	25.07	22.23
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	52.17	8.25	10.85	75.00	99.14
	Total expenses	347.03	81.96	152.48	537.85	642.73
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	30.48	4.92	73.49	48.30	74.44
4	Other income	25.04	6.52	2.83	46.19	5.98
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	55.52	11.43	76.32	94.49	80.42
6	Finance costs	4.13	9.32	4.11	20.95	15.36
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	51.40	2.11	72.21	73.54	65.06
8	Exceptional items	0.81		1.00	0.81	1.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	50.58	2.11	71.21	72.73	64.06
10	Tax expense	14.01		12.40	14.01	12.40
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	36.57	2.11	58.81	58.72	51.66
12	Minority interest *					
13	Net profit/(loss) after taxes minority interest and share of profit/ (loss) of associates (13+14+ 15)	36.57	2.11	58.81	58.72	51.66
14	Paid-up equity share capital	1627.38	1627.38	1627.38	1627.38	1627.38
	(Face Value of the Share shall be indicated)	10	10	10	10	10
15	Reserve excluding Revaluation Reserves				-1162.99	-1220.02
16.i	Earnings per share (before extraordinary items)					
	(of Rs. 10/- each) (not annualised):					
	(a) Basic	0.0225	0.0013	0.361	0.361	0.317
	(b) Diluted					
16.ii	Earnings per share (after extraordinary items)					
	(of Rs. 10/- each) (not annualised):					
	(a) Basic	0.225	0.013	0.361	0.361	0.317
	(b) Diluted					



See accompanying note to the financial results

PART II


	Particulars	For the Quarter ended March 31, 2015	For the Quarter ended December 31, 2014	For the Quarter ended March 31, 2014	Audited For The Year Ended March 31, 2015	Audited For The Year Ended March 31, 2014
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	- Number of shares	8655100	8655100	8655100	8655100	8655100
	- Percentage of shareholding	53.18	53.18	53.18	53.18	53.18
2	Promoters and Promoter Group Shareholding **					
a)	Pledged / Encumbered	Nil	Nil	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b)	Non - encumbered					
	- Number of shares	7618700	7618700	7618700	7618700	7618700
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	46.82	46.82	46.82	46.82	46.82

	Particulars	3 months ended
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	Nil

Notes

- The above Audited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 30th May 2015
- The Company has been engaged in Pharmaceutical, chemicals and Plastic business accordingly separate segment under Accounting Standard -AS 17 reported.
- Pursuant to Companies Act, 2013 become effective from 1st April 2014, the Company has Computed the depreciation based on the useful life of the assets as prescribed in Schedule II of the Act.
- The figure for the last quarter ended 31st March 2015 are the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year.
- Figures pertaining to previous periods have been regrouped and rearranged wherever necessary.

Date : 30.05.2015	For Biofil Chemicals & Pharmaceuticals Limited
Place : Indore	RAMESH SHAH
	MANAGING DIRECTOR
	DIN: 00028819



BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.
AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 31-03-2015
CIN NO. L24233MP1985PLC002709


(In Rs.)

Standalone / Consolidated Statement of Assets and Liabilities		standalone	
		31, March 2015	31, March 2014
Particulars		Audited	Audited
A	EQUITY & LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	162738000	162738000
	(b) Reserves & Surplus	-78590326	-84108795
	(c) Money received against share warrants		
	Sub-total - Shareholders' funds	84147674	78629205
2	Share application money pending allotment		
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings		
	(b) Deferred tax liabilities (net)		
	(c) Other long-term liabilities		
	(d) Long-term provisions		
	Sub-total Non-current liabilities		
5	Current liabilities		
	(a) Short-term borrowings	29800596	28705158
	(b) Trade payables	21109002	36357692
	(c) Other current liabilities	-	-
	(d) Short-term provisions	2505553	2294621
	Sub-total Current liabilities	53415151	67357471
	TOTAL - EQUITY AND LIABILITIES	137562825	145986676
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	Tangible Assests	90576538	91732634
	(b) Goodwill on consolidation *		
	(c) Non-current investments		
	(d) Deferred tax assets (net)		
	(e) Long-term loans and advances		
	(f) Other non-current assets		
	Sub-total - Non-current assets	90576538	91732634
2	Current assets		
	Current investments		
	Inventories	1664534	2735670
	Trade receivables	36512233	41041109
	Cash and cash equivalents	1276152	1792975
	Short-term loans and advances	5279724	6153148
	Other current assets	2253644	2531139
	Sub-total - Current assets	46986287	54254042
	TOTAL - ASSETS	137562825	145986676

DATE : 30-05-2015
PLACE : INDORE


BIOFIL CHEMICALS & PHARMACEUTICALS

RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709
Segmentwise Revenue, Results an Capital Employed for year ended 31st March 2015 (Under Clause 41 Listing Agreement)

S.No.	Segment Revenue	Quarter Ended			Year Ended	
		March 31 ,	December 31,	March 31 ,	31 March	31 March
		2015	2014	2014	2015	2014
		Audited	Reviewed	Audited	Audited	Audited
1	Segment Revenue					
	Pharma Unit	338.10	32.84	210.69	418.30	545.97
	Chemicals Division	39.35	27.79	62.99	130.45	144.65
	Plastic Division	15.68	10.63	0.54	37.40	26.54
	Other	15.94	15.62	3.34	46.19	5.98
	Gross Turnover	409.07	86.88	277.57	632.34	723.15
2	Segment Results					
	Pharma Unit	88.14	1.77	83.75	102.66	158.68
	Chemicals Division	(35.30)	5.25	(78.94)	(10.32)	(70.35)
	Plastic Division	6.93	(2.11)	(29.94)	(0.11)	(7.52)
	Other	(4.70)	6.52	0.07	1.82	(1.12)
	Total Segment Profit Before Tax	55.08	11.43	(25.06)	94.06	79.69
	Interest Income	0.30	0.00	0.43	0.30	0.43
	Interest Expenses	3.99	9.32	3.82	20.81	15.07
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	51.38	2.11	(28.45)	73.54	65.05
	Provision for current tax	14.01	0.00	12.32	14.01	12.40
	Item Related Earlier Year	0.81			0.81	1.00
	Profit After Tax	36.56	2.11	(40.77)	58.72	51.66
3	Capital Employed					
	(Segment Assets- Segment Liabilities)					
	Pharma Unit	146.02	177.46	137.25	146.02	137.25
	Chemicals Division	727.16	672.80	689.52	727.16	689.52
	Plastic Division	(45.72)	(32.99)	(52.88)	(45.72)	(52.88)
	Other	0.00	(1.90)	-	0.00	-
	Total Capital Employed	827.46	815.36	773.90	827.46	773.90

DATE : 30-05-2015
PLACE : INDORE
BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819
